May 02, 2025

Adavosertib in Recurrent or Persistent Uterine Serous Carcinoma

In the phase IIb ADAGIO trial, reported in the Journal of Clinical Oncology, Liu et al found that the Wee1 inhibitor adavosertib showed some activity in patients with recurrent or persistent uterine s...

The ASCO Post

April 29, 2025

Patient-Reported Outcomes With Mirvetuximab Soravtansine vs Chemotherapy in FRα-Positive, Platinum-Resistant Ovarian Cancer

An analysis of the phase III MIRASOL trial evaluated quality-of-life outcomes in patients receiving mirvetuximab soravtansine vs chemotherapy for FRα-positive, platinum-resistant ovarian cancer.

The ASCO Post

April 24, 2025

SGO’s President-Elect Brings Professional Experience and Passion to Her New Role

Society of Gynecologic Oncology (SGO) President-Elect Karen Lu, MD, assumed her official duties on March 17, 2025. Dr. Lu, who is also Executive Vice President and Physician-in-Chief at Moffitt Cance...

The ASCO Post

March 28, 2025

Radiotherapy Alone Following Radical Hysterectomy for Cervical Cancer: Should It Remain the Standard of Care?

The phase III NRG Oncology GOG-0263 trial—results of which were presented during the Plenary Session of the Society of Gynecologic Oncology (SGO) 2025 Annual Meeting on Women’s Cancer—examined whether...

The ASCO Post

March 29, 2023

Positive Outcomes Demonstrated in Patients With Ovarian Cancer Treated With Olaparib Prior to Surgical Intervention and Subsequent Chemotherapy

Treatment with the poly (ADP-ribose) polymerase inhibitor olaparib prior to surgical intervention and chemotherapy has demonstrated the potential for favorable surgical options, manageable adverse eve...

The ASCO Post

March 28, 2024

Chemoradiotherapy With or Without Pembrolizumab for Newly Diagnosed, High-Risk, Locally Advanced Cervical Cancer

The phase III ENGOT-cx11/GOG-3047/KEYNOTE-A18 trial investigated the efficacy and safety of adding pembrolizumab to chemoradiotherapy in patients with newly diagnosed, high-risk, locally advanced cerv...

The ASCO Post

April 25, 2024

Expert Point of View: Gini F. Fleming, MD

Exciting updates from the Society of Gynecologic Oncology Annual Meeting on Women’s Cancer highlight significant improvements in advanced or recurrent endometrial cancer treatment, particularly for patients with specific genetic profiles. Leading expert Dr. Gini F. Fleming shares insights on new approaches and ongoing trials.

The ASCO Post

February 19, 2025

Pembrolizumab in Previously Treated Advanced Clear Cell Gynecological Cancers

“Advanced clear cell gynecological cancers (CCGCs) have a poor prognosis, with response rates to second-line chemotherapy less than 8%. Preliminary clinical activity with PD-1 inhibitors reported in C...

The ASCO Post

May 11, 2023

Poor Tolerability Appears to Hinder Benefit of Adavosertib in Uterine Serous Carcinoma

A new Wee1 kinase inhibitor, adavosertib, showed promising antitumor activity but also raised safety concerns in patients with recurrent or persistent uterine serous carcinoma. The findings were presented by Joyce F. Liu, MD, MPH at the Society of Gynecologic Oncology 2023 Annual Meeting on Women’s Cancer.

The ASCO Post